Q3 Positive Data from tQT/QTc Study soon to be released.
Here is your sneak peak... Short Squeeze coming soon...
Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: computer-assisted intravital microscopy study.
Cheung AT, Chan MS, Ramanujam S, Rangaswami A, Curl K, Franklin P, Wun T.
Departmentsof Pathology and Laboratory Medicine, UC Davis School of Medicine, Davis, CA, USA. firstname.lastname@example.org
Nine patients with sickle cell disease (SCD) who were hospitalized at UC Davis Medical Center for vaso-occlusive crisis (VOC) were studied as part of a randomized double-blind phase III clinical trial to investigate the real-time effects of poloxamer 188 on VOC. All patients showed significant microvascular changes from normal (steady-state) values during VOC (diminished venular diameter and red cell velocity). The patients were randomly assigned to be treated with poloxamer 188 or placebo. Poloxamer 188 (n = 4) but not placebo (n = 5) significantly reversed these microvascular changes approximately 2 hours postinitiation of loading infusion (100 mg/kg in 1 hour). Further significant improvement induced by poloxamer 188 but not placebo was observed or = 7 hours postinfusion, resulting in a significant reversal of the microvascular changes to steady-state values.
How significant determine the how much the impact of this study. The size is small, so better be really significant, I mean everyone can tell the difference without using statistic analysis to show "significant" effect.